CORE BUSINESS
Exobiosphere is the world’s first contract research organization dedicated to high-throughput testing and drug discovery in space. By combining space-grade lab automation, microgravity research, and advanced analytics, the company helps pharmaceutical, biotech, and healthcare partners enhance scientific discovery and accelerate product development. Its Orbital High-Throughput Screening platform (OHTS) is designed to uncover novel cellular and disease behaviors in a microgravity environment—insights that are difficult or impossible to replicate on Earth. Headquartered in Luxembourg at the House of BioHealth, Exobiosphere’s mission is to shorten R&D timelines and bring safer, more effective treatments to market for patients worldwide.
PRODUCTS & SERVICES
Our Orbital High-Throughput Screener (OHTS) enables 2,000+ automated experiments per mission in microgravity. We offer pre-clinical screening, disease modeling, and compound validation services through space-enabled platforms. Partners gain unique insights into drug behavior, improving R&D efficiency and success rates.
Exobiosphere provides end-to-end services to conduct autonomous biological experiments in space, managing all scientific, technical, and operational aspects. The company supports partners through assay development, miniaturization, and adaptation for microgravity; payload integration and biosafety compliance; mission planning and launch logistics; and fully autonomous in-orbit operations requiring no astronaut intervention. Post-mission, Exobiosphere offers sample recovery and advanced analysis, including multi-omics profiling and high-content imaging. These services allow clients to uncover insights into cellular aging, stem cell biology, neurodegeneration, and drug responses that are difficult or impossible to study on Earth.
TECHNICAL MEANS
The OHTS is a fully automated, compact screening lab designed for use in microgravity. It features nanoliter dispensing, compatibility with 384-1536-well plates, real-time data transfer, and AI-integrated analysis. The system integrates seamlessly with orbital carriers and offers modular, pharma-standard infrastructure for repeatable R&D in space.
At the heart of Exobiosphere’s operations is the Orbital High-Throughput Screener (OHTS), a fully autonomous, space-ready biolab designed for microgravity research. The OHTS integrates fluidics, environmental control, high-resolution imaging, and automated workflows in a compact format. It supports parallelized experiments using standard multiwell plates, enabling thousands of conditions to be tested simultaneously in a highly standardized, reproducible way. The system allows live monitoring, automated media handling, compound delivery, and sample preservation for post-flight analysis. Once returned to Earth, these samples can undergo multi-omics and high-content imaging (HCI), unlocking insights into cellular behavior and disease pathways under spaceflight conditions and advancing drug discovery and health research.
MAIN CUSTOMERS
Pharmaceutical and biotech companies, health tech AI companies, research institutes, and space-focused health agencies interested in high-throughput drug screening and disease modeling using microgravity platforms.
MAJOR SPACE PROJECTS
Exobiosphere is the first private biotech company from Luxembourg to successfully test high-throughput biotech hardware in a microgravity environment via parabolic flight. In 2026, we will launch our first orbital mission to deploy the Orbital High-Throughput Screener (OHTS), capable of running thousands of automated assays in space. We've signed a strategic MoU with Space Cargo Unlimited to integrate OHTS aboard BentoBox—a reentry-capable orbital lab. Additional partners include Formulatrix for nanoliter liquid handling, and support from the Luxembourg Space Agency. These projects lay the foundation for Europe's first sovereign, end-to-end space drug discovery pipeline.
